Ibrance (palbociclib), an orally administered kinase inhibitor developed by Pfizer, is facing upcoming patent expirations in the United States. These expirations are crucial for understanding when generic versions of the drug may become available.
When Does Ibrance Patent Exclusivity Expire in the US?
Pfizer's primary U.S. patent for Ibrance, U.S. Patent No. 9,956,416, is currently set to expire on June 19, 2027 [1]. This patent covers the compound itself. However, there are other patents related to Ibrance, including those covering specific formulations and methods of use, which may extend exclusivity in certain contexts [2]. DrugPatentWatch.com tracks these patent expiries, providing detailed timelines for pharmaceuticals like Ibrance [1].
Are There Other Patents Protecting Ibrance?
Beyond the compound patent, Pfizer holds additional patents related to Ibrance. These can include patents for crystalline forms, pharmaceutical compositions, and methods of treatment. The expiration dates of these secondary patents can vary, potentially impacting the timeline for generic market entry for specific indications or formulations [2].
What Happens After the Main Ibrance Patent Expires?
Once the primary U.S. patent for Ibrance expires, the market is generally opened for generic manufacturers to seek approval for their own versions of the drug. This typically involves submitting an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA), demonstrating bioequivalence to the reference listed drug, Ibrance [3]. The availability of generic Ibrance could lead to increased competition and potentially lower drug prices for patients and healthcare systems.
Can Generic Ibrance Enter the Market Before Patent Expiration?
Generic entry before patent expiration typically occurs if a patent is successfully challenged in court or if specific agreements are reached between the innovator company and generic manufacturers. Litigation over drug patents is common, and court rulings can alter the effective exclusivity period for a medication [4].
How Does Ibrance Compare to Other Breast Cancer Treatments?
Ibrance is a targeted therapy approved for certain types of advanced or metastatic breast cancer, specifically hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, often in combination with an aromatase inhibitor or fulvestrant [5]. It functions by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which play a role in cell cycle progression [6]. Other CDK4/6 inhibitors available for similar indications include Verzenio (abemaciclib) from Eli Lilly and Kisqali (ribociclib) from Novartis [7]. These drugs offer alternative treatment options, and their comparative efficacy, safety profiles, and cost can influence prescribing decisions [8].
Who Manufactures Ibrance?
Ibrance is manufactured and marketed by Pfizer Inc. [1].
---
Sources:
[1] DrugPatentWatch.com: https://drugpatentwatch.com/
[2] U.S. Patent and Trademark Office Database (Patent search required for specific patent numbers and their status)
[3] U.S. Food and Drug Administration: https://www.fda.gov/drugs/abbreviated-new-drug-applications-andras/and-generics-overview
[4] U.S. Food and Drug Administration: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cdert/patent-term-restoration
[5] Pfizer Inc. (Ibrance prescribing information)
[6] National Cancer Institute: https://www.cancer.gov/
[7] ClinicalTrials.gov (for comparative study information)
[8] Various medical journals and health organizations (e.g., Journal of Clinical Oncology, American Society of Clinical Oncology)